Avid­i­ty to raise $400M; Sato pays Ar­cutis $25M up­front to li­cense top­i­cal rof­lu­mi­last in Japan

Plus, news about Xen­cor, Ot­su­ka, Type­writer Ther­a­peu­tics, Cas­sa­va Sci­ences, En­ver­ic Bio­sciences, Viking Ther­a­peu­tics and Janux Ther­a­peu­tics:

Next up in the PIPE bo­nan­za: RNA com­pa­ny Avid­i­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER